A Phase II trial to evaluate the safety and efficacy of ATIR101 for the adjunctive treatment in hematopoietic stem cell transplantation (HSCT) pediatric patients with a hematologic malignancy, who are eligible for an HSCT but without the availability of a fully matched donor

Trial Profile

A Phase II trial to evaluate the safety and efficacy of ATIR101 for the adjunctive treatment in hematopoietic stem cell transplantation (HSCT) pediatric patients with a hematologic malignancy, who are eligible for an HSCT but without the availability of a fully matched donor

Planning
Phase of Trial: Phase II

Latest Information Update: 03 Apr 2017

At a glance

  • Drugs T cell replacement therapy TH 9402 (Primary)
  • Indications Graft-versus-host disease; Haematological malignancies
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top